Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD

References

• GardinerCGottMPayneSExploring the care needs of patients with advanced COPD: an overview of the literatureRespir Med2010104215916519818590
   PubMed Web of Science ®Google Scholar
• MurrayCJLopezADAlternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease studyLancet19973499064149815049167458
   PubMed Web of Science ®Google Scholar
• Soler-CatalunaJJMartinez-GarciaMARoman SanchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• SpencerSJonesPWGroup GSTime course of recovery of health status following an infective exacerbation of chronic bronchitisThorax200358758959312832673
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
   PubMed Web of Science ®Google Scholar
• ToyELGallagherKFStanleyELSwensenARDuhMSThe economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a reviewCOPD20107321422820486821
   PubMedGoogle Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD) [web-page on the Internet]Global Strategy for the Diagnosis, Management and Prevention of COPD2017 Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/Accessed March 6, 2018
   Google Scholar
• WhitePThorntonHPinnockHGeorgopoulouSBoothHPOver-treatment of COPD with inhaled corticosteroids – implications for safety and costs: cross-sectional observational studyPLoS One2013810e7522124194824
   PubMed Web of Science ®Google Scholar
• KewKMSeniukovichAInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20143CD010115
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• PriceDKeiningerDCosta-ScharplatzMCost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare settingRespir Med2014108121786179325307414
   PubMed Web of Science ®Google Scholar
• Reza Maleki-YazdiMMolimardMKeiningerDLCost effectiveness of the long-acting beta2-adrenergic agonist (LABA)/long-acting muscarinic antagonist dual bronchodilator indacaterol/glycopyrronium versus the LABA/inhaled corticosteroid combination salmeterol/fluticasone in patients with chronic obstructive pulmonary disease: analyses conducted for Canada, France, Italy, and PortugalAppl Health Econ Health Policy201614557959427516088
   PubMed Web of Science ®Google Scholar
• AsukaiYBaldwinMFonsecaTGrayAMungapenLPriceDImproving clinical reality in chronic obstructive pulmonary disease economic modellingPharmacoeconomics201331215116123329431
   PubMed Web of Science ®Google Scholar
• FalaschettiELaihoJPrimatestaPPurdonSPrediction equations for normal and low lung function from the Health Survey for EnglandEur Respir J200423345646315065839
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanDEffectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in them treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200216681084109112379552
   PubMed Web of Science ®Google Scholar
• FenwickEMarshallDALevyARNicholGUsing and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillationBMC Health Serv Res200665216623946
   PubMed Web of Science ®Google Scholar
• DahlRJadayelDAlagappanVKTChenUBanerjiDEfficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON studyInt J Chron Obstruct Pulmon Dis2013850150824159259
   PubMed Web of Science ®Google Scholar
• BriggsAHClaxtonKSculpherMJDecision Modelling for Health Economic EvaluationOxfordOxford University Press2006
   Google Scholar
• BrandliOSchindlerCKunzliNKellerRPerruchoudAPLung function in healthy never smoking adults: reference values and lower limits of normal of a Swiss populationThorax19965132772838779131
   PubMed Web of Science ®Google Scholar
• IpMSKoFWLauACUpdated spirometric reference values for adult Chinese in Hong Kong and implications on clinical utilizationChest2006129238439216478856
   PubMed Web of Science ®Google Scholar
• LanghammerAJohnsenRGulsvikAHolmenTLBjermerLForced spirometry reference values for Norwegian adults: the Bronchial Obstruction in Nord-Trondelag studyEur Respir J200118577077911757626
   PubMed Web of Science ®Google Scholar
• RocaJBurgosFSunyerJReferences values for forced spirometry. Group of the European Community Respiratory Health SurveyEur Respir J1998116135413629657579
   PubMed Web of Science ®Google Scholar
• ScanlonPDConnettJEWallerLASmoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health studyAm J Respir Crit Care Med20001612 pt 138139010673175
   PubMed Web of Science ®Google Scholar
• LindbergALarssonLGMuellerovaHRonmarkELundbackBUp-to-date on mortality in COPD – report from the OLIN COPD studyBMC Pulm Med201212122230685
   PubMed Web of Science ®Google Scholar
• Department of Statistics, Ministry of the Interior [homepage on the Internet]Abridged Life Table 20132013 Available from: http://sowf.moi.gov.tw/stat/year/y02-11.xlsAccessed April 29, 2014
   Google Scholar
• VestboJGroup TSThe TORCH (towards a revolution in COPD health) survival study protocolEur Respir J200424220621015332386
   PubMed Web of Science ®Google Scholar
• DahlRJadayelDAlagappanVChenHBanerjiDEfficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]International Journal of Chronic Obstructive Pulmonary Disease20149
   Web of Science ®Google Scholar
• Rutten-van MolkenMPOostenbrinkJBTashkinDPBurkhartDMonzBUDoes quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?Chest200613041117112817035446
   PubMed Web of Science ®Google Scholar
• World Health OrganizationCost-Effectiveness Thresholds-Choosing Interventions That Are Cost Effective (WHO-CHOICE) Available from: http://www.who.int/choice/cost-effectiveness/en/Accessed March 13, 2018
   Google Scholar
• ZhongNWangCZhouXLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
   PubMed Web of Science ®Google Scholar
• DrummondMMethods for the Economic Evaluation of Health Care Programmes4th edOxford, UK; New York, NYOxford University Press2015
   Google Scholar